|Day Low/High||10.13 / 10.81|
|52 Wk Low/High||7.56 / 15.45|
The mailbag returns with questions about Northwest Biotherapeutics, Flamel and, of course, Dendreon.
The stock is fighting the underperformance of a second-generation heart drug.
Cramer answers questions, buying Google's dip, Ed Zander countdown, and a pure kosher play.
The stock rises on unusual volume as news of an acquisition emerges.
Still, traders try to pick them as they happen. Volume can help.
We're seeing the worst churn-and-burn environment in more than a year.
The company will get up to $165 million for a diabetes drug it is developing.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.